Cogent Biosciences, Inc. is a clinical-stage biotechnology company focused on developing precision therapies for genetically defined diseases. The company designs rational precision therapies to treat the underlying cause of disease and improve patient lives. Its most advanced program is bezuclastinib, a highly selective tyrosine kinase inhibitor targeting the KIT D816V mutation and other KIT exon 17 mutations for systemic mastocytosis and gastrointestinal stromal tumors.

Cogent Biosciences generates revenue through the development and potential commercialization of its drug candidates, primarily bezuclastinib, which is being developed for systemic mastocytosis and gastrointestinal stromal tumors. The company has not yet commercialized any products and currently relies on licensing agreements, milestone payments, and potential future royalties from its lead asset. Revenue is expected to commence upon regulatory approval and commercial launch of bezuclastinib in the United States, anticipated in the second half of 2026.

The company operates through the following segments: bezuclastinib for systemic mastocytosis, bezuclastinib for gastrointestinal stromal tumors, CGT4859 (FGFR2/3 inhibitor), CGT4255 (ErbB2 inhibitor), CGT6297 (PI3Kα inhibitor), KRAS program, and JAK2 program.

• Bezuclastinib for systemic mastocytosis: This segment focuses on developing bezuclastinib to treat patients with Non-Advanced Systemic Mastocytosis (NonAdvSM) and Advanced Systemic Mastocytosis (AdvSM). Bezuclastinib is designed to potently inhibit the KIT D816V mutation, which drives the majority of systemic mastocytosis cases. The company reported positive top-line results from the registrational SUMMIT trial for NonAdvSM and the APEX trial for AdvSM in 2025, with New Drug Application submissions planned for 2026.

• Bezuclastinib for gastrointestinal stromal tumors: This segment develops bezuclastinib in combination with sunitinib for patients with imatinib-resistant gastrointestinal stromal tumors (GIST). Bezuclastinib targets KIT exon 17 mutations, and the combination showed a 50% reduction in risk of disease progression or death compared to sunitinib monotherapy in the PEAK Phase 3 trial. The company announced FDA acceptance of the NDA under Real-Time Oncology Review in January 2026 and expects to complete submission in April 2026.

• CGT4859 (FGFR2/3 inhibitor): This segment advances a novel FGFR2/3 inhibitor for tumors bearing FGFR2/3 mutations, including advanced cholangiocarcinoma. The company is actively enrolling patients in a Phase 1 study to evaluate safety, tolerability, and clinical activity, with data expected in 2026. CGT4859 is designed to address limitations of existing FGFR inhibitors, such as dose-limiting hyperphosphatemia.

• CGT4255 (ErbB2 inhibitor): This segment develops a CNS-penetrant, selective mutant ErbB2 inhibitor for solid tumors with brain metastasis, particularly HER2-mutant lung cancer. The company received FDA clearance on its IND submission and initiated a Phase 1 dose escalation study in the fourth quarter of 2025. CGT4255 aims to overcome limitations of existing HER2 tyrosine kinase inhibitors that lack sufficient brain penetration.

• CGT6297 (PI3Kα inhibitor): This segment develops a wild-type-sparing PI3Kα inhibitor targeting the H1047R, E542K, and E545K mutants, which affect over 30,000 cancer patients annually. IND-enabling studies have been completed, and an IND application was submitted in the fourth quarter of 2025, with a Phase 1 dose escalation expected in the first quarter of 2026. The inhibitor is designed to avoid dose limitations caused by activity against wild-type PI3Kα.

• KRAS program: This segment focuses on developing a potent and selective KRAS inhibitor for prevalent mutations in colorectal, non-small cell lung, and pancreatic cancers. The company plans to submit an IND for this program in 2026 to address limitations of existing KRAS-targeted therapies.

• JAK2 program: This segment develops a novel wild-type-sparing JAK2 V617F mutant-selective inhibitor for myeloproliferative neoplasms, including polycythemia vera and essential thrombocythemia. The JAK2 V617F mutation occurs in approximately 95% of polycythemia vera patients and 50% of essential thrombocythemia patients. The company plans to submit an IND for this program in 2026.

Cogent Biosciences operates in the competitive biotechnology industry focused on precision medicines for genetically defined diseases, facing competition from large pharmaceutical companies such as Blueprint Medicines (a Sanofi company), Novartis AG, Pfizer Inc., Bayer HealthCare Pharmaceuticals, and Deciphera Pharmaceuticals. The company's competitive advantages include the high selectivity and potency of bezuclastinib for KIT mutations, its limited blood-brain-barrier penetration reducing potential central nervous system toxicities, and Breakthrough Therapy Designations from the FDA for bezuclastinib in both systemic mastocytosis and gastrointestinal stromal tumors.

Cogent Biosciences serves patients with rare, genetically driven diseases, including those with systemic mastocytosis (both Non-Advanced and Advanced forms) and gastrointestinal stromal tumors who have progressed on prior therapies. The company also targets patients with FGFR2/3-mutant cholangiocarcinoma, HER2-mutant solid tumors with brain metastasis, PI3Kα-mutant cancers, KRAS-mutant cancers, and JAK2 V617F-mutant myeloproliferative neoplasms. Specific customer or patient names are not disclosed in the filing.